Update - Clinical commissioning policies
NHS Central East Integrated Care Board (ICB) was formed on 1 April 2026 and is the successor ICB to NHS Bedfordshire, Luton and Milton Keynes ICB, NHS Cambridgeshire & Peterborough ICB and the Hertfordshire part of NHS Hertfordshire and West Essex ICB. NHS Central East ICB had transferred to it the property, rights and liabilities of the predecessor organisations. The actions and decisions of the predecessor organisation, including relevant clinical commissioning policies, relevant prescribing decisions and recommendations and relevant clinical pathways continue in effect. There are differences in places between some clinical commissioning policies, prescribing recommendations and pathways, from the predecessor ICBs.
Clinical policies transferred to NHS Central East ICB from each of the relevant predecessor ICBs remain applicable to each part of the population for who they were originally created. These different policies will continue to apply to the relevant populations unless or until any new policy is adopted by the NHS Central East ICB (after public involvement if required).
We are in the process of developing a new NHS Central East ICB website for clinical commissioning policies, pathways and prescribing information. During this transition period, clinicians, providers, patients and the public can continue to access all legacy policies, prescribing recommendations, and pathways via the legacy ICB websites. Where legacy policies, are superseded by new NHS Central East ICB policies, this will be clearly indicated on the relevant legacy policy and published on the new Central East website in advance of implementation.
If you have any questions or concerns do continue to contact your local teams at the following legacy ICBs:
NHS Hertfordshire and West Essex ICB
The documents in this section are currently being reviewed and remediated into an accessible format. If the document you require, is not available, please contact Prescribing Partnership for a copy.
- Attention Deficiency Hyperactive Disorder in Children and Young People
- Alemtuzumab for relapsing-remitting multiple sclerosis
- Apomorphine use in Parkinsons disease
- Azathioprine & 6-mercaptopurine Adults for inflammatory conditions
- Azathioprine & 6-mercaptopurine treatment for paediatric gastroenterology and hepatology patients
- Bosentan for digital ulcers in systemic sclerosis
- Ciclosporin in adult services
- Cinacalcet for the management of primary and secondary hyperparathyroidism
- Colistin Colistimethate sodium for the treatment of lung infections of non-cystic fibrosis - PAPWORTH
- Dapsone - Dermatitis Herpetiformis and other Dermatose
- Denosumab
- Dexamfetamine Excessive sleepiness associated with narcolepsy
- Fluoxetine, sertraline and citalopram for the treatment of depression and anxiety in children and young people aged 11-17
- Gentamicin for Nebulisation (PAPWORTH)
- Gentamicin for nebulisation
- Hydroxycarbamide for myeloproliferative disorders and sickle cell disease for patients within adult services
- Hydroxychloroquine for patients within adult services
- Inhaled Colistimethate sodium (nebulised) for the treatment of lung infections of non-cystic fibrosis
- Leflunomide for patients in adult services
- Methotrexate
- Methylphenidate - excessive sleepiness associated with narcolepsy
- Methylphenidate, Dexamfetamine, Lisdexamfetamine for Adults with Attention Deficiency Hyperactive Disorder
- Midodrine for orthostatic hypertension and neurocardiogenic syncope
- Modafinil for narcolepsy - Papworth
- Mycophenolate mofetil (MMF) use in multisystem autoimmune disease
- Nintedanib for idiopathic pulmonary fibrosis
- Patiromer calcium for persistent hyperkalaemia in adults with chronic kidney disease or heart failure
- Penicillamine (Wilsons disease)
- Pirfenidone for idiopathic pulmonary fibrosis
- Riluzole for amyotrophic lateral sclerosis form of MND
- Sodium zirconium cyclosilicate for persistant hyperkalaemia in adults with chronic kidney disease or heart failure
- Sulfasalazine for patients in adult services
- Tolvaptan for autosomal dominant polycystic kidney disease
- Triptorelin 4 weekly administration/ 12 weekly administration - Precocious Puberty